# ISO 5910:2018 (E)

## Cardiovascular implants and extracorporeal systems — Cardiac valve repair devices

## Contents

1

2

3

4

5

6

7

Foreword Introduction Scope Normative references Terms and definitions Abbreviations **Fundamental requirements** 5.1 General 5.2 **Risk management Device description** 6.1 Intended use/Indication for use 6.2 **Design inputs** 6.2.1 General **Operational specifications** 6.2.2 6.2.3 Functional, performance and safety requirements 6.2.3.1 General Implantable device 6.2.3.2 6.2.3.3 Delivery system (if applicable) 6.2.4 Usability 6.2.5 Packaging, labelling, and sterilization **Design outputs** 6.3 Design transfer (manufacturing verification/validation) 6.4 Design verification testing and analysis / Design validation 7.1 **General requirements** In vitro assessment 7.2 7.2.1 General Test articles, sample selection, test conditions and reporting requirements 7.2.2 7.2.2.1 Test articles and sample selection 7.2.2.2 **Test conditions Reporting requirements** 7.2.2.3 7.2.3 Device material property assessment 7.2.3.1 General 7.2.3.2 **Biological safety** Material property testing 7.2.3.3

- Functional performance assessment 7.2.4
- Device structural performance assessment 7.2.5
- General 7.2.5.1
- 7.2.5.2 Structural component fatigue assessment
- Device durability assessment 7.2.5.3
- 7.2.6 **Device corrosion assessment**
- 7.2.7 Delivery system design evaluation requirements
- 7.2.8 Visibility
- Simulated use assessment 7.2.9
- Human factors / Usability assessment 7.2.10
- 7.2.11 **Device MRI safety**

- 7.2.12 Design specific testing
- 7.3 Preclinical in vivo evaluation
- 7.3.1 General
- 7.3.2 Overall requirements
- 7.3.3 Methods
- 7.3.4 Test report
- 7.4 Clinical Investigations
- 7.4.1 General
- 7.4.2 Study considerations
- 7.4.2.1 General
- 7.4.2.2 Direct Visualization Surgical Devices
- 7.4.2.3 Transcatheter Devices
- 7.4.3 Study endpoints
- 7.4.4 Ethical considerations
- 7.4.5 Distribution of subjects and investigators
- 7.4.6 Statistical considerations including sample size and duration
- 7.4.7 Patient selection criteria
- 7.4.8 Clinical data requirements
- 7.4.8.1 General
- 7.4.8.2 Baseline
- 7.4.8.3 Peri-Procedure Data
- 7.4.8.4 Follow-Up Data
- 7.4.9 Clinical investigation analysis and reporting
- 7.4.10 Post-market clinical follow-up

Annex A (informative) Rationale for the provisions of this document

- A.1 Rationale for risk based approach
- A.2 Rationale for preclinical in vivo evaluation
- A.3 Rationale for design verification and design validation testing
- A.4 Rationale for imaging assessment
- A.5 Rationale for clinical evaluation reporting
- A.6 Rationale for device configuration within labelling and instructions for use
- A.7 Rationale for human factors engineering
- Annex B (informative) Examples of heart valve repair devices and delivery systems
  - B.1 General
  - B.2 Examples of heart valve repair devices
  - B.3 Examples of heart valve repair device delivery systems
- Annex C (normative) Packaging
  - C.1 Requirements
  - C.2 Principle
  - C.3 Containers
  - C.3.1 Unit container(s)
  - C.3.2 Outer container

#### Annex D (normative) Product labels, instructions for use, and training

- D.1 Requirements
- D.1.1 General
- D.1.2 Unit-container label
- D.1.3 Outer-container label
- D.1.4 Instructions for use
- D.1.5 Labels for medical records
- D.2 Training for physicians and support staff
- Annex E (normative) Sterilization
  - E.1 General
- Annex F (informative) Heart valve repair system characteristics
  - F.1 General
  - F.2 Characteristics of heart valve repair device
  - F.3 Characteristics of delivery system
  - F.4 Chemical treatments, surface modifications, or coatings
  - F.5 Implant procedure

- F.6 Accessories
- Annex G (informative) Heart valve repair system hazards, associated failure modes and evaluation methods
  - G.1 General
  - G.2 Hazards, failure modes, and evaluation methods
  - G.3 Failure modes/ hazards related to the delivery system
  - G.4 Additional generic failure modes and causes

#### Annex H (informative) In vitro test guidelines for paediatric devices

- H.1 Introduction and paediatric definitions
- H.2 Pulsatile flow test conditions
- H.3 FEA/life analysis conditions
- Annex I (informative) Examples and definitions of some physical and material properties of heart valve repair device components
  - I.1 General
  - I.2 Bulk physical properties
  - I.3 Surface physical properties
  - I.3.1 General
  - I.4 Mechanical and chemical engineering properties
  - I.5 Nitinol properties
  - I.5.1 General
- Annex J (informative) Examples of standards applicable to testing of materials and components of heart valve repair devices
  - J.1 Metals
  - J.1.1 Specifications for materials for metal implants
  - J.1.2 Tensile test with extensometer to failure
  - J.1.3 Poisson's ratio
  - J.1.4 Durability crack initiation and endurance limit; S-N curves
  - J.1.5 Fatigue crack growth rate; crack growth velocity
  - J.1.6 Hardness
  - J.1.7 Microstructure
  - J.1.8 Thermal expansion
  - J.1.9 Fracture toughness
  - J.1.10 Fatigue life
  - J.1.11 Corrosion
  - J.2 Polymers
  - J.2.1 Viscosimetry
  - J.2.2 Melt flow index
  - J.2.3 Determination of breaking strength under static load
  - J.2.4 Tensile test with extensometer to failure (if possible)
  - J.2.5 Poisson's ratio
  - J.2.6 Determination of dynamic mechanical properties
  - J.2.7 Resistance to surface wear
  - J.2.8 Resistance to scratch
  - J.2.9 Flexural properties; determination of breaking strength under dynamic bending load
  - J.2.10 Fatigue crack initiation and endurance limit; S-N curves
  - J.2.11 Fatigue crack growth rate
  - J.2.12 Determination of compressive properties
  - J.2.13 Specification of surgical implants made from high-density silicone elastomer
  - J.2.14 Density
  - J.2.15 Liquid diffusivity (porosity and permeability; water absorption)
  - J.2.16 Hardness
  - J.2.17 Wear resistance
  - J.2.18 Creep
  - J.2.19 Fracture toughness
  - J.2.20 Hydraulic expansion
  - J.3 Ceramics and carbons
  - J.3.1 Physical and chemical properties
  - J.3.2 Fatigue rate
  - J.3.3 Hardness
  - J.3.4 Thermal expansion

- J.3.5 Fracture toughness
- J.4 Plastic materials
- J.4.1 Possible adaptation of tensile properties
- J.5 Textiles
- J.5.1 Determination of tear-out resistance
- J.5.2 Determination of water absorption
- J.5.3 Determination of breaking strength under static load
- J.5.4 MRI compatibility
- Annex K (informative) Considerations for device material properties undergoing alterations post implantation

#### Annex L (informative) Corrosion assessment

- L.1 Rationale
- L.2 Introduction
- L.3 Pitting corrosion
- L.4 Crevice corrosion
- L.5 Galvanic corrosion
- L.6 Corrosion fatigue
- L.7 Fretting (wear) and fretting corrosion
- L.8 Post-fatigue corrosion evaluation

#### Annex M (informative) Guidelines for in vitro evaluation of functional performance of the repair

- M.1 General
- M.2 Steady back-flow leakage testing
- M.2.1 Measuring equipment accuracy
- M.2.2 Test apparatus requirements
- M.2.3 Test procedure
- M.2.4 Test report
- M.3 Pulsatile-flow testing
- M.3.1 Measuring equipment accuracy
- M.3.2 Test apparatus requirements
- M.3.3 Test procedure
- M.3.4 Test report

### Annex N (informative) Durability testing

- N.1 General
- N.2 Measurement equipment accuracy
- N.3 Test parameters
- N.4 Results evaluation
- N.5 Real time wear testing
- N.6 Dynamic Failure Mode
- N.7 Report requirements
- Annex O (informative) Fatigue assessment
  - O.1 General
  - O.2 Stress/strain analysis of structural components of the heart valve repair device under simulated in vivo conditions
  - 0.3 Fatigue characterization
  - O.3.1 General
  - O.3.2 Stress/life (S/N) characterization
  - O.3.3 Strain/life (ε/N) characterization
  - 0.3.4 Fatigue crack growth (da/dN) characterization
  - O.3.5 Component testing
  - 0.4 Fatigue lifetime assessment
  - O.4.1 General
  - 0.4.2 Stress-life (S/N) assessment
  - 0.4.3 Strain-life (ε/N) assessment
  - O.4.4 Damage tolerance analysis (DTA)
  - 0.4.5 Component demonstration assessment
  - O.4.6 Test to Failure
  - O.4.7 Post Fatigue Evaluation

Annex P (informative) Preclinical in vivo evaluation

- P.1 General
- P.2 Definitions
- P.3 Evaluations
- P.3.1 Haemodynamic performance
- P.3.2 Ease of use
- P.3.3 Device migration or embolisation
- P.3.4 Interference with or damage to adjacent anatomical structures
- P.3.5 Haemolysis
- P.3.6 Thromboembolic events
- P.3.7 Calcification/mineralization
- P.3.8 Pannus formation/tissue ingrowth
- P.3.9 Structural and non-structural dysfunction
- P.3.10 Assessment of device and non-device related pathology

#### Annex Q (normative) Adverse event classification during clinical investigation

- Q.1 General
- Q.2 Evaluation
- Q.3 Data collection requirements
- Q.4 Adverse events
- Q.5 Adverse device effects
- Q.6 Device deficiencies
- Q.7 Classification of causal relationships
- Q.8 Classification of adverse events
- Q.8.1 General
- Q.8.2 Examples of adverse events
- Q.9 Comparison to surgical valve repair
- Q.10 Outcome Severity Rankings
- Q.11 Follow up of SAEs
- Annex R (informative) Imaging protocol
  - R.1 General
  - R.2 Echocardiographic studies
  - R.3 Data collected
  - R.4 Computed Tomography (CT) studies
  - R.5 Cardiac Magnetic Resonance (CMR)
- Annex S (informative) Clinical investigation endpoints for valve repair devices: Suggestions for endpoints and their timing
  - S.1 General
  - S.2 Single endpoints
  - S.2.1 General
  - S.2.2 Safety
  - S.2.3 Performance and Effectiveness
  - S.2.4 Heart failure hospitalization definition
  - S.2.5 Composite endpoints
  - S.2.6 Timing of endpoints

#### Annex T (informative) Additional device design evaluation requirements

- T.1 General
- T.2 Device migration resistance
- T.3 Implant foreshortening (length to diameter)
- T.4 Crush resistance
- T.5 Recoil (balloon expandable stents)
- T.6 Radial resistive force
- T.7 Chronic Outward Force (COF)
- T.8 Anatomic interactions
- Annex U (informative) Guidelines for delivery system design evaluation
  - U.1 General
  - U.2 Implant interactions with delivery system
  - U.3 Loading/ attachment of device to delivery system
  - U.4 Ability to access and deploy

Page count: 126